Pipeline new from Stealth Biotherapeutics, Translate Bio, Adynxx, and BiondVax Pharmaceuticals

April 16, 2018

Company Drug/Device Medical Condition Status
Abbott optical coherence tomography (OTC) high-risk, complex coronary artery disease Phase I trials initiated enrolling 3,650 subjects in North America, Europe and Asia
Translate Bio MRT5005 first-in-human clinical trial in patients with cystic fibrosis Phase I/II clearance given by the FDA
Adynxx Inc. brivoligide (AYX1) post-surgical pain Phase II results announced
GTx, Inc. enobosarm post-menopausal stress urinary incontinence (SUI) Phase II trials initiated enrolling 493 subjects at over 60 clinical trial centers across the U.S.
BiondVax Pharmaceuticals Ltd. M-001 universal flu vaccine Phase II trials initiated enrolling 9,630 subjects age 50 years and older across four-to-six countries over a period of two flu seasons
Therapix Ltd. THX-110 adult subjects with Tourette syndrome Phase IIa topline results announced
AbbVie upadacitinib moderate to severe Rheumatoid Arthritis Phase III topline results announced evaluating 37 subjects
Stealth Biotherapeutics elamipretide Barth syndrome Orphan Drug Designation granted
Clovis Oncology Inc. Rubraca (rucaparib) tablets adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy FDA approval granted